Literature DB >> 15709062

Preventing type 2 diabetes mellitus.

Jeff Curtis1, Charlton Wilson.   

Abstract

Type 2 diabetes is a serious, costly, and increasingly common disease. Several conditions commonly seen in family medicine settings confer increased risk of developing diabetes. Among these conditions are impaired glucose tolerance, impaired fasting glucose, obesity, gestational diabetes, hypertension, hyperlipidemia, and menopause. We here present the results of a systematic review of the literature examining the evidence for different strategies aimed at preventing type 2 diabetes in patients with these conditions. The strongest evidence supports an intensive lifestyle intervention designed to induce modest weight loss. The greatest degree of prevention, based on lesser quality evidence, may be imparted by bariatric surgery. Metformin and troglitazone have appreciable evidence in specific populations, and orlistat and acarbose have slightly less evidence among obese patients, for preventing diabetes. Ramipril, captopril, losartan, pravastatin, and estrogens show some very preliminary promise for preventing diabetes in patients treated for hypertension, hyperlipidemia, and menopause, but each needs a more rigorous evaluation. Although more questions remain to be answered, family physicians now have tools available to help our patients lead lives free of diabetes.

Entities:  

Mesh:

Year:  2005        PMID: 15709062     DOI: 10.3122/jabfm.18.1.37

Source DB:  PubMed          Journal:  J Am Board Fam Pract        ISSN: 0893-8652


  3 in total

1.  Systematic Review of the Effect of Lifestyle Interventions on the Components of the Metabolic Syndrome in South Asian Migrants.

Authors:  Catherine A Martin; Usha Gowda; Ben J Smith; Andre M N Renzaho
Journal:  J Immigr Minor Health       Date:  2018-02

Review 2.  Complexity of type 2 diabetes mellitus data sets emerging from nutrigenomic research: a case for dimensionality reduction?

Authors:  Jim Kaput; Kevin Dawson
Journal:  Mutat Res       Date:  2007-05-05       Impact factor: 2.433

Review 3.  Overviews of pathogen emergence: which pathogens emerge, when and why?

Authors:  S Cleaveland; D T Haydon; L Taylor
Journal:  Curr Top Microbiol Immunol       Date:  2007       Impact factor: 4.291

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.